Veeva Systems Inc. (VEEV)
| Market Cap | 48.82B +0.3% |
| Revenue (ttm) | 3.46B +16.5% |
| Net Income | 1.01B +25.3% |
| EPS | 6.10 +25.5% |
| Shares Out | 161.91M |
| PE Ratio | 49.43 |
| Forward PE | 31.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 750,244 |
| Open | 305.36 |
| Previous Close | 302.42 |
| Day's Range | 299.36 - 305.36 |
| 52-Week Range | 148.05 - 325.99 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 326.41 (+8.25%) |
| Earnings Date | Dec 3, 2026 |
About VEEV
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides ... [Read more]
Financial Performance
In fiscal year 2026, Veeva Systems's revenue was $3.20 billion, an increase of 16.34% compared to the previous year's $2.75 billion. Earnings were $908.91 million, an increase of 27.27%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for VEEV stock is "Buy." The 12-month stock price target is $326.41, which is an increase of 8.25% from the latest price.
News
Veeva to Release Fiscal 2027 Third Quarter Results on December 3, 2026
PLEASANTON, Calif., Nov. 12, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its third quarter ending October 31, 2026 after market close on December 3, 2026.
Veeva price target raised to $400 from $330 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Veeva (VEEV) to $400 from $330 and keeps an Overweight rating on the shares. The firm sees $1B AI…
Veeva price target raised to $360 from $305 at Truist
Truist raised the firm’s price target on Veeva (VEEV) to $360 from $305 and keeps a Buy rating on the shares. The firm has come away “encouraged” by the breadth…
Veeva price target raised to $315 from $260 at Canaccord
Canaccord analyst David Hynes raised the firm’s price target on Veeva (VEEV) to $315 from $260 and keeps a Hold rating on the shares. The firm said its investor day…
Veeva price target raised to $360 from $340 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Veeva (VEEV) to $360 from $340 and keeps a Buy rating on the shares. The company’s annual Investor Day event…
Veeva price target raised to $365 from $325 at RBC Capital
RBC Capital analyst Rishi Jaluria raised the firm’s price target on Veeva (VEEV) to $365 from $325 and keeps an Outperform rating on the shares after the company’s Investor Day…
Veeva price target raised to $375 from $295 at Jefferies
Jefferies raised the firm’s price target on Veeva (VEEV) to $375 from $295 and keeps a Buy rating on the shares. Veeva’s $6B calendar year 2030 target is unchanged, but…
Veeva price target raised to $325 from $290 at UBS
UBS analyst Karl Keirstead raised the firm’s price target on Veeva (VEEV) to $325 from $290 and keeps a Neutral rating on the shares. Veeva reaffirmed its CY30 targets of…
Veeva price target raised to $340 from $300 at Stifel
Stifel raised the firm’s price target on Veeva (VEEV) to $340 from $300 and keeps a Buy rating on the shares.
Veeva Systems Transcript: Investor Day 2026
TAM rose to $30B, up $10B YoY, as AI expands the opportunity; the $6B 2030 revenue run-rate goal remains on track and does not rely on new AI products. Priorities include scaling Falcon, Vault AI, Quality Cloud and CRO-focused Study Suite.
Veeva Systems Slides: FY 2026
Veeva Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 5, 2026.
UCB Selects Veeva Vault CRM
Agentic CRM platform to drive unified engagement worldwide PLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB has committed to Veeva Vault CRM, the ag...
Veeva price target raised to $345 from $280 at Mizuho
Mizuho raised the firm’s price target on Veeva (VEEV) to $345 from $280 and keeps an Outperform rating on the shares.
Veeva price target raised to $375 from $360 at Barclays
Barclays raised the firm’s price target on Veeva (VEEV) to $375 from $360 and keeps an Overweight rating on the shares.
Veeva price target raised to $350 from $300 at Baird
Baird raised the firm’s price target on Veeva (VEEV) to $350 from $300 and keeps an Outperform rating on the shares.
Veeva Survives Selling Pressure, Nearing its All-Time High
Veeva Systems, Inc. (VEEV) shares are up 1,062% since institutions first bought big in 2015.
Veeva moves lower after report says OpenAI buying Orchestra Bio
Veeva (VEEV) shares moved off their session highs after Axios reported that OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development. Pu...
Veeva price target raised to $360 from $315 at Barclays
Barclays raised the firm’s price target on Veeva (VEEV) to $360 from $315 and keeps an Overweight rating on the shares after hosting meetings with management. The firm left feeling…
Veeva to Host Virtual Investor Day on November 5, 2026
PLEASANTON, Calif., Oct. 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026.
Iqvia selects Veeva clinical operations applications
IQVIA (IQV) and Veeva Systems (VEEV) announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will…
IQVIA Selects Veeva Clinical Operations Applications
RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, ...
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswir...
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging ...
Veeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies
Automates data reconciliation, saving clinical teams significant cost, time, and effort PLEASANTON, Calif., Oct. 6, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva DQS (Data...